Foley Catheter Related Bladder Discomfort (FCRBD): Role of Neutrophil Cells

Sponsor
Washington University School of Medicine (Other)
Overall Status
Terminated
CT.gov ID
NCT03118284
Collaborator
(none)
58
1
9.2
6.3

Study Details

Study Description

Brief Summary

Urinary [Foley] catheters [tubes] are commonly placed in patients undergoing surgery; approximately 25% of surgical patients will receive one. Among patients who receive urinary catheters, discomfort associated with the Foley catheter is common; between 47-90% of patients experience catheter related bladder discomfort [CRBD]. Presence of a foreign object in the bladder even for short periods of time may result in symptoms such as a burning sensation, pain in the lower abdomen, muscle spasms and a sense of urgency to urinate. There is some evidence that suggests that hospital-acquired urinary tract infections are directly related to catheter placement, which causes mechanical damage and local inflammation to the urethra and the bladder. Based on research conducted on a similar mechanism where an airway tube is inserted into a patients throat for delivery of general anesthesia - we hypothesize that CRBD is related to injury and inflammation caused by the catheter placement and that this occurs in a sterile environment.

Condition or Disease Intervention/Treatment Phase
  • Other: urine collection
  • Other: Blood collection
  • Behavioral: NRS

Detailed Description

Urinary catheterization has been implicated in up to 80% of hospital-acquired UTIs, and has been associated with evidence for immunological and histological damage frequently in the absence of bacteria31. In a recent human study in elderly patients with ASB and UTI analysis of neutrophil activity showed evidence of enzymatic involvement during bladder infection32, and some appeared to relate to pain and inflammation, however no analysis was conducted regarding neutrophil phenotypes and the impact of mtDNA on sterile local injury mediated exclusively by a Foley catheter.

The bladder irritation that results from Foley catheterization appears to be mediated by muscarinic receptors that mediate involuntary bladder smooth-muscle contractility. Thus the main therapy relies on agents with anti-muscarinic activity such as oxybutynin, tolterodine and butylscopolamine, whereas some benefit has been shown with tramadol, ketamine, paracetamol, pregabalin and gabapentin. However no single commonly accepted therapy for FCRBD is available, and there is uncertainty about the safety and efficacy of the current treatments available. Some research has suggested a role for inflammatory mediators in the occurrence of FCRBD as evident by induction of prostaglandin synthesis and cyclooxygenase-2 (COX-2) inhibitors alleviating symptoms related to FCRBD. In summary various therapies to control FCRBD are available but none have directly addressed the acute inflammatory reaction likely mediating these symptoms1,2,3,4. Hence our interest in analyzing the activity of acute inflammatory cells in particular neutrophil activation as a mediator of bladder inflammation and trigger of FCRBD.

Although the exact pathophysiology of FCRBD has not been elucidated, we recently showed expression of inflammatory mediators, neutrophil infiltration and mucosal surface injury in the absence of bacterial infection using a human model of tracheal injury. As it has been clearly shown that neutrophil infiltration and activation can be driven in response to sterile cell death8, our preliminary data suggest that the link between Foley catheter and possible bladder neutrophil accumulation is through mucosal cell injury.

Study Design

Study Type:
Observational
Actual Enrollment :
58 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Foley Catheter Related Bladder Discomfort (FCRBD): Role of Neutrophil Cells
Actual Study Start Date :
Nov 21, 2016
Actual Primary Completion Date :
Aug 21, 2017
Actual Study Completion Date :
Aug 28, 2017

Arms and Interventions

Arm Intervention/Treatment
Foley catheter group

Urine collection and blood collection and NRS for pain in patients having surgery for which their surgeon has ordered placement of a Foley catheter.

Other: urine collection

Other: Blood collection

Behavioral: NRS

Healthy control group

Blood collection in healthy volunteers from the Research Participant Registry or recruited from posters around the Washington University campus

Other: Blood collection

Outcome Measures

Primary Outcome Measures

  1. Neutrophil surface marker changes in subjects that experience Foley catheter related bladder discomfort [FCRBD] [Change from baseline [immediately after catheter placement] until catheter removal [post-operative day 1, 2, 3].]

    Changes in surface inflammatory markers on polymorphonuclear neutrophils associated with bladder injury secondary to Foley catheter placement.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Ages 18 to 75.

  2. American Society of Anesthesiologists Physical Status Classification (ASA) I, II, and III, per CPAP assessment.

  3. Planned Foley catheter placement with surgery and hospitalization.

  4. Scheduled elective surgery (i.e., orthopedic, neurosurgical, spine surgery, cardiac, thoracic surgery, ear nose and throat surgery).

  5. Anticipated length of Foley catheter requirement up to 72 hours.

  6. Ability to provide informed consent.

Exclusion Criteria:
  1. Visible blood in the urine as evident upon sample collection.

  2. More than one attempt to place the Foley catheter as documented by RN in OR.

  3. Planned surgical procedure involving the urinary system

  4. On dialysis and/or anuric

  5. Urinary tract infection (UTI) as documented by primary team within 24 hours of surgery

  6. Pregnancy or lactating.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Washington University in St Louis Saint Louis Missouri United States 63110

Sponsors and Collaborators

  • Washington University School of Medicine

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT03118284
Other Study ID Numbers:
  • 201609072
First Posted:
Apr 18, 2017
Last Update Posted:
Nov 15, 2018
Last Verified:
Nov 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Washington University School of Medicine

Study Results

No Results Posted as of Nov 15, 2018